

JERRY BAGEL, M.D., M.S.
Schweiger Dermatology Group
Psoriasis Treatment Center of New Jersey
Eczema Treatment Center of New Jersey

59 One Mile Road Ext.
East Windsor, NJ 08520
Phone: (609) 443-4500 Fax: (609) 443-4030
schweigerderm.com
dreamacres1@aol.com

Jerry Bagel
10/24/23

PSORIASIS & ECZEMA TREATMENT CENTER

1985 – Present Director, Psoriasis Treatment Center of New Jersey;
Director, Eczema Treatment Center of New Jersey
Facilities include PUVA, narrow band UVB, hand/foot phototherapy,
systemic therapy, biological therapy, excimer laser and clinical trials.

EDUCATION AND TRAINING

2023 – Present Schweiger Dermatology Group, Clinical Dermatology
1985 – 2023 Windsor Dermatology Private Practice, Clinical Dermatology
1982 – 1985 Dermatology Resident
College of Physicians and Surgeons – Columbia University
1981 – 1982 Internship in Internal Medicine – Jackson Memorial Medical Center
University of Miami – School of Medicine
1981 M.D. Mt. Sinai School of Medicine
1977 M.S. in Biochemistry – Rutgers University
1975 B.A. cum laude in Biology – Boston University
1971 Graduated Salutatorian – Hightstown High School

LICENSURE

1985 Board Certification in American Board of Dermatology
1985 New Jersey Medical License #25MA04445900

PRECEPTORSHIP

11/2022 Leo Pharma
8/2021 Educational Development and Preceptor
Windsor Dermatology in partnership with UCB Biopharma
6/2021 Educational Development and Preceptor
Windsor Dermatology in partnership with Bristol Myers Squibb

CLINICAL TRIALS

- 2023 A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis. Sponsored by Takeda.
- 2023 A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Non-Pustular Palmoplantar and Genital Psoriasis. Sponsored by Bristol Myers Squibb.
- 2023 A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged 12 to 18 years With Moderate-to-severe Atopic Dermatitis. Sponsored by Amgen.
- 2023 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Plaque Psoriasis in Participants with at Least Moderate Severity Affecting Special Areas or Lower Body Surface Area. Sponsored by Janssen.
- 2023 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis. Sponsored by Janssen.
- 2023 A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment. Sponsored by Janssen.
- 2023 A Single-Center, Open-Label Study to Evaluate Tralokinumab in Atopic Dermatitis Subjects Who Experienced Inadequate Response on Dupilumab. Sponsored by Jerry Bagel.
- 2023 A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate to Severe Genital Psoriasis or Moderate to Severe Scalp Psoriasis. Sponsored by Abbvie.

- 2023 A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa. Sponsored by Incyte.
- 2023 An Open-Label Study to Evaluate the Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participants with Moderate-to-Severe Atopic Dermatitis Previously Treated with Dupilumab. Sponsored by Eli Lilly.
- 2023 A Phase 3B/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Moderate-to-Severe Psoriasis. Sponsored by Bristol-Myers Squibb.
- 2023 PSoSA (PSoriasis Special Areas) - a US-based, Single-Arm, Prospective, Multicenter, Observational Study of Nail and Scalp Psoriasis Improvement in Patients Treated with Ixekizumab. Sponsored by Eli Lilly.
- 2023 A Single Center, Observational Study to Evaluate the Effectiveness and Safety of Cryotherapy in combination with 10% ALA gel Red light PDT in the treatment of Actinic Keratosis on the Full Face. Sponsored by Jerry Bagel.
- 2023 A Single Center Study to Evaluate the Effectiveness and Safety of SOTYKTU® (deucravacitinib) in Combination with Enstilar for Moderate to Severe Plaque Psoriasis. Sponsored by Jerry Bagel.
- 2023 Tralokinumab Real world Clinical use: An observational cohort study of atopic dermatitis patients prescribed tralokinumab. Sponsored by Leo Pharma.
- 2022 A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Janssen.
- 2022 A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Skin of Color who have Moderate-to-Severe Plaque Psoriasis and/or Moderate-to-Severe Scalp Psoriasis. Sponsored by Janssen.
- 2022 A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Janssen.
- 2022 Hidradenitis Suppurativa: Lutikizumab (ABT-981) Versus Placebo for Adult Subjects with Moderate to Severe Hidradenitis Suppurativa. Sponsored by Abbvie.

- 2022 Single Center, Pilot Study to Evaluate the Effectiveness and Safety of Dupilumab in Combination with Narrowband UVB (nUVB) Phototherapy in the Treatment of Moderate-to-Severe Atopic Dermatitis. Sponsored by Jerry Bagel.
- 2022 Inflammatory Skin Disease Treatment Identification Study. Sponsored by Castle Biosciences, Inc.
- 2022 A Phase 2b Multicenter, Randomized, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Janssen.
- 2021 A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Seborrheic Dermatitis. Sponsored by Arcutis Biotherapeutics, Inc.
- 2021 A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects with Scalp and Body Psoriasis. Sponsored by Arcutis Biotherapeutics, Inc.
- 2021 A Multi-Center, Exploratory Study to Assess Dupilumab Effect on Pruritus Neuro-Mechanisms in Patients with Atopic Dermatitis. Sponsored by Sanofi-Aventis Recherche & Développement.
- 2021 Risankizumab in Moderate to Severe Plaque Psoriasis Patients with Palmoplantar Involvement. Sponsored by Abbvie.
- 2021 A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants with Moderate To Severe Hidradenitis Suppurativa. Sponsored by UCB Biopharma.
- 2021 A Multicenter, Open Registry of Patients with Psoriasis Who Are Candidates for Systemic Therapy Including Biologics. Sponsored by Janssen.
- 2021 Corrona Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness. Sponsored by CorEvitas.
- 2021 A Multicenter, Randomized, Double-blinded Study Evaluating the Pharmacokinetics, Efficacy and Safety of Multiple Switches Between Ustekinumab and ABP 654 Compared with Continued Use of Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Amgen.

- 2021 A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.15% and ARQ-151 Cream 0.05% in Subjects with Atopic Dermatitis. Sponsored by Arcutis Biotherapeutics, Inc.
- 2021 A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects with Atopic Dermatitis. Sponsored by Arcutis Biotherapeutics, Inc.
- 2021 A Phase 2b, Multicenter, Randomized, Placebo-and Active-comparator-controlled, Double-blind Study to Evaluate the Safety and Efficacy of Bermekimab (JNJ-77474462) for the Treatment of Participants with Moderate to Severe Atopic Dermatitis. Sponsored by Janssen.
- 2021 A Phase 3, Multicenter, Randomized, Double-Blind Study Evaluating the Efficacy and Safety of ABP 654 Compared with Ustekinumab in Subjects With Moderate to Severe Plaque Psoriasis. Sponsored by Amgen.
- 2021 A Phase 2a, Proof of Concept, 24-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects with Non-Segmental Facial Vitiligo. Sponsored by Arcutis Biotherapeutics, Inc.
- 2021 A Multicenter, Randomized, Double-Blinded, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Topically Applied Sofpironium Bromide Gel, 15% in Subjects with Axillary Hyperhidrosis (the "Cardigan II Study"). Sponsored by Brickell Biotech, Inc.
- 2021 A Long-Term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis. Sponsored by Dermira, Inc.
- 2021 A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients with Moderate-to-Severe Atopic Dermatitis. Sponsored by Eli Lilly.
- 2021 An Exploratory, Multicenter, Observational Study to Examine RNA Biomarkers of Psoriasis Subjects Through the Application of the Mindera Kit Part 2 (STAMP-2). Sponsored by Mindera Corporation.
- 2020 A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis. Sponsored by Joel M Gelfand MD MSCE.

- 2020 A Study to Test Long-Term Treatment with Spesolimab in People with Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies with Spesolimab. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
- 2020 Corrona Atopic Dermatitis Registry. Sponsored by Corrona, LLC
- 2020 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination with Topical Corticosteroid Treatment in Patients With Moderate-To-Severe Atopic Dermatitis. Sponsored by Dermira, Inc.
- 2020 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa. Sponsored by Abbvie.
- 2020 A Phase 3, Multicenter, Open-Label Extension Study of the Long-Term Safety of ARQ-151 Cream 0.3% in Subjects with Chronic Plaque Psoriasis. Sponsored by Arcutis Biotherapeutics, Inc.
- 2020 A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination with Topical Corticosteroid Treatment in Patients with Moderate-to-Severe Atopic Dermatitis. Sponsored by Dermira.
- 2020 A Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of Secukinumab 300 mg Over 32 Weeks in Adult Patients with Biopsy-Proven Forms of Lichen Planus Not Adequately Controlled with Topical Therapies. Sponsored by Novartis.
- 2020 Open Label Study, Evaluating Taltz in combination with Enstilar (calcipotriene and betamethasone dipropionate) Foam in Psoriasis Patients. Sponsored by Jerry Bagel.
- 2020 A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants with Moderate to Severe Hidradenitis Suppurativa. Sponsored by UCB.
- 2020 A Single Center Study to Evaluate the Effectiveness and Safety of ILUMYA in Combination with HALOG Ointment 0.1% for the Treatment of Moderate to Severe Plaque Psoriasis. Sponsored by Jerry Bagel.
- 2020 A Phase 3, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.3% Administered QD in Subjects with Chronic Plaque Psoriasis. Sponsored by Arcutis, Inc.

- 2020 A pragmatic trial of home versus office based narrow band ultraviolet B phototherapy for the treatment of psoriasis. Sponsored by PCORI.
- 2019 Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated with Biologic Agents. Sponsored by Jerry Bagel.
- 2019 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Efficacy and Safety of Tildrakizumab in the Treatment of Moderate to Severe Plaque Psoriasis of the Scalp. Sponsored by Sun Pharma.
- 2019 Multi-Center, Double-Blind, Randomised, Placebo-Controlled, Phase IIb Dose-Finding Study to Evaluate Efficacy and Safety of Different Subcutaneous Doses of BI 655130 in Patients with Moderate to Severe Palmoplantar Pustulosis (PPP). Sponsored by Boehringer Ingelheim.
- 2019 A Phase 3 Efficacy and Safety Study of Tapinarof for the Treatment of Plaque Psoriasis in Adults. Sponsored by Dermavant Sciences
- 2019 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Risankizumab Using a New Formulation for the Treatment of Adult Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Abbvie.
- 2019 A 16 week, Randomized, Open Label, Multicenter Study to Assess the Superiority of Secukinumab over Guselkumab in the Complete Treatment of Ustekinumab-Resistant Psoriatic Plaques- Arrow. Sponsored by Novartis.
- 2019 A Phase 2B, Randomized, Double Blind, Vehicle Controlled, Parallel-Group, Dose Ranging Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of PF-06700841 Topical Cream Applied Once or Twice Daily for 12 Weeks in Participants with Mild to Moderate Chronic Plaque Psoriasis. Sponsored by Pfizer.
- 2019 An Outcomes Study to Determine the Reasons Patients on Biologic Therapy Discontinue Treatment and Fail to Follow-up With Their Providers. Sponsored by Jerry Bagel.
- 2019 A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions. Sponsored by Target Pharmasolutions.
- 2019 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects with Moderate to Severe Atopic Dermatitis. Sponsored by Abbvie.

- 2018 Risankizumab versus Secukinumab for Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Abbvie
- 2018 A Phase 3, Multicenter, Randomized, Double-Blind Study with an Active-Controlled Initial Treatment Period Followed by a Dose-Blind Maintenance Treatment Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by UCB.
- 2018 A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Effect of Tralokinumab on Vaccine Antibody Responses in Adults with Moderate-to-Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy. Sponsored by Leo Pharma.
- 2018 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by UCB.
- 2018 A Randomized, Double Blind, Placebo Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritis in Adults with Prurigo Nodularis. Sponsored by Menlo Therapeutics.
- 2018 A Study to Evaluate the Safety and Efficacy of Brodalumab in Subjects with Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies. Sponsored by Icahn School of Medicine at Mount Sinai.
- 2018 Skin Biopsy Analysis for Inflammatory Skin Disorders. Sponsored by Jerry Bagel, MD.
- 2018 A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritis in Adults with Plaque Psoriasis. Sponsored by Menlo Therapeutics.
- 2017 CC-10004-SPSO-001 A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp (STYLE). Sponsored by Celgene
- 2017 Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) (ECZTRA 2) Sponsored by LEO Pharma.
- 2017 Safety, Efficacy, and Tolerability of SNA-120 in Subjects With Pruritus Associated With Psoriasis Vulgaris. Sponsored by Sienna Biopharmaceuticals
- 2017 A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp (AK003). Sponsored by Athenex, Inc.

- 2017 A Study to Evaluate the Safety and Efficacy of CLS006 Versus Vehicle in Subjects 2 Years of Age or Older With Cutaneous Common Warts Sponsored by Cutanea Life Sciences, Inc.
- 2017 An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis Patients. Sponsored by Psoriasis Treatment Center of Central New Jersey
- 2017 A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis (ECLIPSE). Sponsored by Janssen Research & Development, LLC
- 2017 Enstilar in Combination With Biologic Agents. Sponsored by Psoriasis Treatment Center of Central New Jersey.
- 2017 A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis (LIMMITLESS). Sponsored by AbbVie.
- 2017 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study to Explore changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment with Secukinumab, Compared to Placebo, and Up to 52 Weeks of Treatment with Secukinumab in Adult Patients with Moderate to Severe Plaque Psoriasis. Sponsored by Novartis.
- 2017 A Phase 2A, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate Safety and Efficacy of PF-06700841 in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Pfizer.
- 2017 An Open-Label, Observational Study Evaluating Enstilar (calcipotriene and betamethasone dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated with Biologic Agents. Sponsored by Jerry Bagel.
- 2017 An Open-Label, Randomized, Actual Use Study of Dupilumab Auto-Injector Device in Patients with Atopic Dermatitis. Sponsored by Regeneron
- 2017 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients from 6 to Less than 18 Years of Age with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly and Company.
- 2017 LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris. Sponsored by LEO Pharma A/S.
- 2016 A Randomised, Double-blind, Vehicle-Controlled, Phase IIb

- Study to Assess the Efficacy and Safety of Topically Applied DS107 Cream to Adults with Mild to Moderate Atopic Dermatitis. Sponsored by DSBiopharma.
- 2016 A Phase 2b Multicenter, Randomized, Placebo-Controlled, Double-Blind Dose-Ranging Study to Evaluate ABT-494 in Adult Subjects with Moderate to Severe Atopic Dermatitis. Sponsored by Abbvie
- 2016 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Site Study to Evaluate the Therapeutic Equivalence of a Generic Pimecrolimus Cream 1% (Glenmark Pharmaceuticals Ltd) to the Marketed Product Elidel (pimecrolimus) Cream 1% (Valeant Pharmaceuticals North America LLC) in the Treatment of Mild to Moderate Atopic Dermatitis. Sponsored by Glenmark Pharmaceuticals Ltd.
- 2016 A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly.
- 2016 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose Finding Study to Evaluate the Safety, Tolerability and Efficacy of KD-025 in Adult Subjects with Moderate to Severe Chronic Plaque Psoriasis who are Candidates for Systemic Therapy or Phototherapy. Sponsored by Kadmon.
- 2016 2016 A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects with Moderate Chronic Plaque Type Psoriasis. Sponsored by Lycera Corp.
- 2016 A 52-Week, Multi-Center, Randomized, Double-Blind, Study of Secukinumab (300mg) to Demonstrate Efficacy as Assessed by Psoriasis Area and Severity Index and Investigators Global Assessment After 12 Weeks of Treatment, Compared to Ustekinumab, and to Assess Long-Term Safety, Tolerability, and Efficacy in Subjects with Moderate to Severe Plaque Psoriasis. Sponsored by Novartis.
- 2016 An Open-Label, Observational Study Evaluating Topicort Topical Spray 0.25% (desoximetasone) in Patients with Scalp Psoriasis. Sponsored by Jerry Bagel.
- 2016 Open Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Failed Therapy with Apremilast. Sponsored by Amgen
- 2016 A Phase IIB, Randomized, Double-Blind, Randomized, Placebo Controlled, Parallel, Multicenter, Dose Ranging, Study To Evaluate the Efficacy and Safety Profile of PF-04965842 in Subjects with Moderate to Severe Atopic Dermatitis. Sponsored by Pfizer.
- 2016 Concept Elicitation, Cognitive Debriefing, and Usability Testing in Chronic Plaque Psoriasis. Sponsored by Endpoint.

- 2016 A PROspective, observational, US-based study assessing outcomes, adverse events, treatment patterns, and quality of life in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma and treated with Valchlor. Sponsored by Actelion.
- 2016 An Open-Label, Observational Study Evaluating Topicort Topical Spray 0.25% (desoximetasone) BID in Psoriasis Patients Being Treated with Biologic Agents. Sponsored by Jerry Bagel
- 2015 Corrona Psoriasis Registry. Sponsored by Corrona, LLC
- 2015 A Phase III, Multi-Center, Double-Blind, Randomized, Vehicle Controlled Clinical Study To Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. Sponsored by Dow Pharmaceutical Sciences.
- 2015 A Phase III, Multi-Center, Open Label Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis. Sponsored by Dow Pharmaceutical Sciences.
- 2015 A Multi-Center, Randomized, Double-Blind Study Comparing the Efficacy and Safety of Ixekizumab Dosing Regimens in Patients with Moderate-to-Severe Plaque Psoriasis. Sponsored by Eli Lilly and Company.
- 2015 An Open Label Extension Trial Assessing the Safety and Efficacy of BI 655066 Administered Subcutaneously in Patients with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by Boehringer Ingelheim Pharmaceuticals, Inc.
- 2015 A Prospective, Observational, US-Based Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed with Mycosis Fungoides Cutaneous T-Cell Lymphoma and Treated with Valchlor. Sponsored by Actelion Pharmaceuticals US, Inc.
- 2015 A Phase IV, Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004), in Subjects with Moderate Plaque Psoriasis. Sponsored by Celgene Corporation.
- 2015 An Open-Label Study of Dupilimab in Patients with Atopic Dermatitis who participated in Previous Dupilimab Clinical Trials. Sponsored by Regeneron Pharmaceuticals, Inc.
- 2015 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Multiple Dupilimab Dose Regimens Administered as Monotherapy For Maintaining Treatment Response in Patients with Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.

- 2015 Single-Center, Two Phase, Pilot Study to Evaluate the Efficacy and Safety of Combining Otezla® (apremilast) 30mg BID in Combination with Narrowband UVB (nUVB) Phototherapy, to Determine Effectiveness of Otezla® in Promoting Maintenance of Response in the Treatment of Moderate-to-Severe Plaque Psoriasis. Sponsored by Jerry Bagel, MD
- 2015 Randomized, Phase 2, Double-Blind, Vehicle-Controlled Trial to Evaluate the Safety and Efficacy of Q301 Cream in Patients with Moderate to Severe Atopic Dermatitis. Sponsored by Qurient
- 2014 A Phase 3 Confirmatory Study Investigating the Efficacy and Safety of Dupilimab Monotherapy Administered to Adult Patients with Moderate-To-Severe Atopic Dermatitis. Sponsored by Regeneron Pharmaceuticals, Inc.
- 2014 A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by A Dose-Blind and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pego in Subjects with Moderate to Severe Chronic Plaque Psoriasis. Sponsored by UBC Biopharma, SPRL
- 2014 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis. Sponsored by Janssen Research & Development, LLC
- 2014 A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Demonstrate the Efficacy of Subcutaneous Secukinumab [300mg] as Assessed by the Psoriasis Scalp Severity Index (PSSI) at 12 Weeks of Treatment, Compared to Placebo, and Assess Safety and Tolerability Up to 24 Weeks in Adult Subjects with Moderate to Severe Scalp Psoriasis. Sponsored by Novartis Pharmaceuticals Corporation
- 2014 Characterization of Chronic Inflammatory Skin Disease. Sponsored by TRBIO
- 2014 A Small Methods Study Involving Electronic Data Collection in Normal Care Settings with Adult Psoriasis Patients Who Have A High Level of Clearance (As Determined by sPGA of 0 or 1) And Are Currently Being Treated With A Biologic. Sponsored by HRA
- 2014 LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects with Psoriasis Vulgaris. Sponsored by Leo Pharma
- 2014 A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis. Sponsored by Valeant

- 2014 A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Subjects with Chronic Plaque Psoriasis. Sponsored by AbbVie
- 2014 A 52-week, multicenter, randomized, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 16 weeks of treatment compared to ustekinumab and to assess long-term safety, tolerability and efficacy in subjects with Moderate to severe plaque psoriasis. Sponsored by Novartis
- 2014 A 48 weeks study of three different dose regimens of BI 655066 Administered subcutaneously in patients with moderate to severe Chronic plaque psoriasis (randomized, dose-ranging, active-comparator controlled (ustekinumab), double-blind within dose groups of BI 655066). Sponsored by Boehringer Ingelheim
- 2013 A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of Halobetasol Propionate Lotion 0.05% Versus Vehicle Lotion in Subjects with Plaque Psoriasis. Sponsored by Therapeutics Inc.
- 2013 An Observational Study to Assess Patient Satisfaction and Control of Psoriasis with Taclonex® Topical Suspension and Effect on Quality of Life. Investigator Sponsored.
- 2013 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter, Parallel Group Study of the Safety of Betamethasone Dipropionate Spray 0.05% versus Diprolene® (augmented betamethasone dipropionate) Lotion 0.05% and the Efficacy of Betamethasone Dipropionate Spray 0.05% versus Vehicle Spray in the Treatment of Moderate Plaque Psoriasis. Sponsored by Promius
- 2013 A Randomized, Vehicle-Controlled, Double-Blind, Parallel-Group, Multi-Center Phase III Study to Evaluate the Safety and Efficacy of the Investigational Drug in Plaque Psoriasis Patients. Sponsored by Maruho
- 2013 Eli Lilly: A 12-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period
- 2013 Eli Lilly: Pharmacokinetic Evaluations of Ixekizumab following Subcutaneous Administration Using Prefilled Syringe or Auto-Injector in Patients with Moderate-to-Severe Plaque Psoriasis
- 2012 Janssen Biotech: A Phase 3b, Randomized, Double-Blind, Active-controlled, Multicenter Study to Evaluate a “Subject-tailored” Maintenance Dosing Approach in Subjects with Moderate-to-Severe Plaque Psoriasis

- 2012 Eli Lilly: Phase 2b A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Phase 2b Study of LY3009104 in Patients with Moderate-to-Severe Plaque Psoriasis
- 2011 Amgen: A Phase 3 Study to Evaluate the Efficacy and Safety of Induction and Maintenance Regimens of Brodalumab Compared With Placebo and Ustekinumab in Subjects with Moderate to Severe Plaque Psoriasis: AMAGINE-3
- 2011 Amgen: Open Label Study to evaluate the efficacy and safety of Entanercept Treatment in Subjects with Moderate to Severe Plaque Psoriasis Who Have Lost a Satisfactory Response to Adalimumab
- 2011 Galderma: A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Parallel Group Study to Demonstrate The Efficacy and Assess The Safety of CD07805/47 Gel 0.5% Applied Topically Once Daily in Subjects with Moderate to Severe Facial Erythema Associated With Rosacea.
- 2011 Anterior Hyperhidrosis: To Evaluate Sweat Production in Subjects With Primary Axillary Hyperhidrosis in Adults.
- 2011 Prometheus: Collection of Blood Samples for Developing Assays to measure Drug Levels and Anti-Drug Antibody Levels in Subjects treated with Humira
- 2011 No compounds 04001: A Multicenter, Observational, Non interventional, Narrative Study to Evaluate Patient-reported Experiences of Living with Moderate to Severe Plaque Psoriasis
- 2010 Celgene: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (Cc-10004) In Subjects with Mild to Severe Plaque Psoriasis
- 2010 Vitiligo: A Single Center, Single-Arm, Open-Label, Pilot Trial to Evaluate The Safety, Effectiveness, and Impact on Quality of Life. Adalimumab Treatment in Adults with Stable Generalized Vitiligo Vulgaris
- 2010 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adding Methotrexate to Entercept in Subjects with Moderate to Severe Plaque Psoriasis
- 2009 – Present Effectiveness and Safety of 3 Dosing Regimens of CP – 690, 550 to Placebo in Subjects with Moderate to Severe Chronic Plaque Psoriasis sponsored by Pfizer
- 2009 – Present Moderate to Severe Plaque Psoriasis with Scalp Involvement sponsored by Amgen

2009 – Present	Trial to Evaluate the Effectiveness and Safety of HUMIRA in Combination with Narrowband UVB (NB-UVB) Phototherapy for the Treatment of Psoriasis sponsored by Abbott
2009	A Controlled Study of Humira in Subjects with Chronic Plaque Psoriasis of Hands and/or Feet
2009	Esprit Registry
2008	Psolar Registry
2007	Observe Registry
2008	Abbott Protocol M06-890: Phase III: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled study comparing the Safety and Efficacy to Two Regimens of ABT-874 to placebo in subjects with moderate to severe chronic plaque psoriasis
2008	Genentech Protocol ACD4412n: A Phase IV Randomized Double-Blind Placebo Controlled Study to Evaluate The Safety and Efficacy of 1.0 Mg/Kg EFALIZUMAB In Adult Patients with Moderate to Severe Plaque Psoriasis with The Involvement of The Scalp.
2008	Atlanta Protocol 0416-01-01: A multi-Center Double-Blind, Randomized, Vehicle Controlled, Parallel-Group Study Comparing Altana Inc's Tacrolimus ointment 0.1% to Protopic (Tacrolimus) Ointment 0.1% and Both Active Treatments to a Vehicle Control in the Treatment of Atopic Dermatitis.
2007	A Single-Center, Prospective, Single-Blind, Pilot Study to Compare the Effect of Diet in Overweight or Obese Patients with Psoriasis on Light Therapy.
2007	A Clinical Evaluation of Safety and Efficacy of Adding Topical Coal Tar Solution to Standard UVB Phototherapy Administered 3 Times Weekly to Patients with Generalized Psoriasis: a Pilot Study.
2007	A Comparative Pharmacokinetic Evaluation of 4% Trade Name (Fluorouracil) Cream Vs Efudex Cream in Patients with Actinic Keratosis: Hill Dermaceuticals Inc.
2005-06	A Phase 3 Multi-centered, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects with Moderate to Severe Plaque-Type Psoriasis: Centocor, Inc.
2005-06	A Phase III, Long-term, Open Label Study to Evaluate the Safety of Twice-daily Tacrolimus Cream-B in the Treatment of Psoriasis: Astellas, Inc.

2005 A Multicenter, Open-label, Pilot Trial to Evaluate the Effectiveness and Safety of Enbrel in Combination with narrowband UVB Phototherapy for the Treatment of Psoriasis: Amgen, Inc.

2005 Safety and Efficacy Evaluation of Tretinoin Gel, 0.05% versus Tretinoin Gel Vehicle in the Treatment of Mild to Moderate Acne Vulgaris: Healthpoint, Ltd.

2005 Point in Time Collection Protocol in Order to Build a Repository of DNA Specimens from Donor/Participants with Genetic and Clinical Signs of Psoriasis with a matched Control Group: BioCollections, Inc.

2004 Atlas Registry

2004 Phase IV Psoriasis Study to Evaluate Safety and Efficacy of an Extended Course of Alefacept, following a Standard 12-Week Course of Amevive: Biogen, Idec.

2004 Phase II Psoriasis Study Evaluations STA S326: Synta Pharmaceuticals

2004 Phase II Psoriasis Study Evaluating Psoraxine/AS210: Astralis, Inc.

2004 Phase 3b Psoriasis Study Evaluating Etanercept: Amgen, Inc.

2004 Phase II Psoriasis Study Evaluating CNTO 1275: Centocor, Inc.

2004 Phase III Psoriasis Study Evaluating 0.3% FK506
Gel vs. Gel Vehicle: Fujisawa Healthcare, Inc.

2003 Phase 1 Psoriasis Study Evaluating IM AS210 in Moderate Psoriasis: Astralis, Ltd.

2004 SQ IL-12 Monoclonal Antibody in Psoriasis: Centocor

2003 Alefacept in Psoriatics Weighing Between 100kg –150kg: Biogen

2003 SQ Enbrel 50mg BIW in Moderate to Severe Psoriasis.

2003 CD4 Antibody Study in Patients with Moderate to Severe Psoriasis: Genmab

2003 Tuporal Capsules in Patients with Moderate to Severe Psoriasis: Stifle Laboratory

2002 A Phase 2, Randomized, Double-Blind Study of 0.1% and 0.5% Tacrolimus Cream Versus Cream Vehicle in the Treatment of Mild to Moderate Plaque Psoriasis in Adults: Fujisawa

2002 SQ ENBREL in Moderate to Severe Psoriasis: Amgen

2002 B-Clear in Localized Psoriasis: Lumenis

2002 Calcitrol 3ug/g Ointment in Psoriasis; Galderma

2001 A Two-Part, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Clinical Trial of ABX-IL8 in Patient with Moderate to Severe Plaque Psoriasis: Abgenix

2001 A Phase 2, Randomized, Double-Blind Study of 0.3% Tacrolimus Gel versus Gel Vehicle in The Treatment Of Mild to Moderate Psoriasis in Adult Subjects: Fujisawa

2001 A Randomized, Double-Blind, Parallel Group Evaluation of Clobetasol Propionate Shampoo, 0.05% versus Its Vehicle – An Efficacy and Safety Study in Subject with Scalp Psoriasis: Galderma

2000 Phase II Psoriasis Study; Evaluating PVAC: Corixa

2000 Phase II Psoriasis Study; Evaluation topical FK8453 Gel: Fujisawa

2001

2000 Phase III Psoriasis Study; evaluating subcutaneous anti-CD11a: Genentech

1999 Evaluate safety of Topical Tacrolimus Ointment for the Treatment of Atopic Dermatitis: Fujisawa

1999 Evaluate Safety and Efficacy of Tazarolene Cream 0.1% in Acne: Allergan

1999 A Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle – Controlled Study of The Efficacy and Safety of Fluticasone Propionate Lotion 0.05% Applied Once Daily for Four Weeks in the Treatment of Adult and Pediatric Subjects with Moderate to Severe Atopic Dermatitis (with GlaxoWellcome).

1998-2002 Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study of BG9273 in subjects with Moderate to Severe Plaque Psoriasis (with Biogen).

1998 Multicenter, Double-Blind, Randomized, Vehicle-Controlled, Study of the Safety and Efficacy of 0.05% and 0.1% Tazarotene Creams applied once daily for 12 weeks in the Treatment of Plaque Psoriasis (with Allergan).

1997 A Double-Blind, Randomized, Parallel Study Comparing Two Formulations of 12% Ammonium Lactate Lotion and a Placebo for the Treatment of Ichthyosis Vulgaris (with Clay Park Labs).

1998

1996 L-733, 725 Multiple Oral Dose Safety, Tolerability, and Biological Activity Study in Psoriatic Patients (with Merck Pharmaceutical).

1997

- 1995 & 1997 Phase II of a Double Blind, Placebo-Controlled, Randomized, Trial of DAB389IL-2 in Patients with Moderate to Severe Plaque Psoriasis (with Seragen Pharmaceutical).
- 1993 – 1994 A Double Blind, Placebo-Controlled, Randomized, Parallel Group Study to Evaluate the Effects of Cyclosporine a on an Ex-Vivo Stimulation Assay and on a Calcineurin Phosphatase Assay In Patients with Chronic Plaque Psoriasis (With Merck Pharmaceutical).

PUBLICATIONS

- 2023 Bagel J, Novak K, Nelson E. Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis. *J Drugs Dermatol.* 2023 Aug 1;22(8):766-772. doi: 10.36849/jdd.6830.
- 2023 Stein Gold LF, Bagel J, Tyring SK, et al. Comparison of risankizumab and apremilast for the treatment of adult patients with moderate plaque psoriasis eligible for systemic therapy: results from a randomised, open-label, assessor-blinded phase IV (IMMpulse) study. *Br J Dermatol.* 2023 Jul 25;ljad252. doi: 10.1093/bjd/ljad252.
- 2023 Bagel J, Gold LS, Del Rosso J, Johnson S, Yamauchi P et al. Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trial. *J Am Acad Dermatol.* 2023 May 10;S0190-9622(23)00771-5. doi: 10.1016/j.jaad.2023.04.061.
- 2023 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, et al. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary. *Immunotherapy.* 2023 Aug;15(11):787-797. doi: 10.2217/imt-2023-0062. Epub 2023 May 7.
- 2023 Blauvelt A, Pariser DM, Tyring S, Bagel J, et al. Psoriasis improvements and inflammatory biomarker normalization with secukinumab: the randomized ObePso-S study. *J Dermatol Sci.* 2023 Jan;109(1):12-21. doi: 10.1016/j.jdermsci.2023.01.003. Epub 2023 Jan 9.
- 2023 Simpson EL, Gooderham M, Wollenberg A, et al. Efficacy and Safety of Lebrikizumab in Combination With Topical Corticosteroids in Adolescents and Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (ADhere). *JAMA Dermatol.* 2023 Feb 1;159(2):182-191. doi: 10.1001/jamadermatol.2022.5534.
- 2023 Abuabara K, Eichenfield LF, Bissonnette R, Silverberg JI, Bagel J, et al. Real-world evidence on atopic dermatitis: Baseline characteristics and predictors of treatment choice in the TARGET cohort. *J Am Acad Dermatol.* 2023 Aug;89(2):345-347. doi: 10.1016/j.jaad.2022.08.065. Epub 2022 Dec 13.

- 2023 Yu C, Wang G, Burge RT, Ye E, Dou G, Li J, Harrison RW, McLean RR, Kerti SJ, Bagel J. Outcomes of Biologic Use in Asian Compared with Non-Hispanic White Adult Psoriasis Patients from the CorEvitas Psoriasis Registry. *Dermatol Ther (Heidelb)*. 2023 Jan;13(1):187-206. doi: 10.1007/s13555-022-00843-6. Epub 2022 Nov 16.
- 2022 Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, Papp KA, Bagel J, et al. Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials. *JAMA*. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632.
- 2022 Strober B, Thaçi D, Sofen H, Kircik L, Gordon KB, Foley P, Rich P, Paul C, Bagel J, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial. *J Am Acad Dermatol*. 2023 Jan;88(1):40-51. doi: 10.1016/j.jaad.2022.08.061. Epub 2022 Sep 14.
- 2022 Bagel J, Nguyen TQ, Lima H, Jain N, Pariser DM, Hsu S, Yosipovitch G, Zhang H, Chao J, Bansal S, Chen Z, Richman D, Korotzer A, Ardeleanu M., Baseline Demographics and Severity and Burden of Atopic Dermatitis in Adult Patients Initiating Dupilumab Treatment in a Real-World Registry (PROSE), *Dermatol Ther (Heidelb)*. 2022 Jun;12(6):1417-1430. doi: 10.1007/s13555-022-00742-w. Epub 2022 May 20.
- 2022 Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Pagnuet B, Charef P, Patekar M, Keefe D., Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial, *Br J Dermatol*. 2022 Jun;186(6):942-954. doi: 10.1111/bjd.20971. Epub 2022 Apr 8.
- 2022 Blauvelt A, Armstrong AW, Langley RG, Gebauer K, Thaçi D, Bagel J, Guenther LC, Paul C, Randazzo B, Flavin S, Hsu MC, You Y, Reich K., Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study, *J Dermatolog Treat*. 2022 Jun;33(4):2317-2324. doi: 10.1080/09546634.2021.1959504. Epub 2021 Aug 4.
- 2022 Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L., Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis, *J Dermatolog Treat*. 2022 Jun;33(4):2085-2093. doi: 10.1080/09546634.2021.1914812. Epub 2021 May 5.
- 2022 Paller AS, Seyger MMB, Magariños GA, Pinter A, Cather JC, Rodriguez-Capriles C, Zhu D, Somani N, Garrelts A, Papp KA; IXORA-PEDS

- Investigators., Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial, *JAMA Dermatol.* 2022 May 1;158(5):533-541. doi: 10.1001/jamadermatol.2022.0655.
- 2022 Bagel J, Nelson E., Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab., *J Drugs Dermatol.* 2022 Mar 1;21(3):235-240. doi: 10.36849/JDD.6396.PMID: 35254755
- 2022 Bagel J, Novak K, Nelson E., Adjunctive Use of Halobetasol Propionate-Tazarotene in Biologic-Experienced Patients With Psoriasis., *Cutis.* 2022 Feb;109(2):103-109. doi: 10.12788/cutis.0451.PMID: 35659807
- 2022 Bagel J, Tatla D, Hellot S, Knapp B, Murphy C, Peterson L, Sebastian M. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis. *J Drugs Dermatol.* 2022 Feb 1;21(2):162-171. doi: 10.36849/jdd.6274.
- 2022 Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, Kircik L, Ehst B, Hong HC, Soung J, Fromowitz J, Guenther S, Piscitelli SC, Rubenstein DS, Brown PM, Tallman AM, Bissonnette R. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. *N Engl J Med.* 2021 Dec 9;385(24):2219-2229. doi: 10.1056/NEJMoa2103629.
- 2022 Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D. Secukinumab dosing every two weeks demonstrated superior efficacy compared with dosing every four weeks in patients with psoriasis weighing 90 kg or more: Results of a randomised controlled trial. *Br J Dermatol.* 2022 Jan 4. doi: 10.1111/bjd.20971. Online ahead of print.
- 2022 Bagel J, Nelson E. Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab. *J Drugs Dermatol.* 2022 Mar 1;21(3):235-240. doi: 10.36849/JDD.6396.PMID: 35254755
- 2022 Bagel J, Novak K, Nelson E. Adjunctive Use of Halobetasol Propionate-Tazarotene in Biologic-Experienced Patients With Psoriasis. *Cutis.* 2022 February;109(2):103-109 | doi:10.12788/cutis.0451
- 2022 Jerry Bagel MD, Daljit Tatla, Scarlett Hellot, Bertram Knapp, Charita Murphy, Luke Peterson, Michael Sebastian MD. Bimekizumab Self-Injection Devices: Two Multicenter, Randomized, Open-Label Studies on Self-Administration by Patients With Psoriasis. Ahead of print. Feb2022 Volume 21 Issue 2 162.
- 2022 Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D.

- Secukinumab dosing every two weeks demonstrated superior efficacy compared with dosing every four weeks in patients with psoriasis weighing 90 kg or more: Results of a randomised controlled trial. *Br J Dermatol.* 2022 Jan 4. doi: 10.1111/bjd.20971. Online ahead of print. PMID: 34981829
- 2022 A.S. Paller, J.K.L. Tan, J. Bagel, A.B. Rossi, B. Shumel, H. Zhang, A. Abramova. IGABSA composite for assessing disease severity and response in patients with atopic dermatitis. *Br J Dermatol* 2022 Mar;186(3):496-507. doi: 10.1111/bjd.20872. Epub 2022 Feb 25.
- 2021 Weingberg J, Lebwohl M. *Advances in Psoriasis A Multisystemic Guide- Apremilast.* Bagel J, Nelson E. Springer Nature Switzerland AG 2021 DOI <https://doi.org/10.1007/978-3-030-54859-9>.
- 2021 Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, Kircik L, Ehst B, Hong HC, Soung J, Fromowitz J, Guenther S, Piscitelli SC, Rubenstein DS, Brown PM, Tallman AM, Bissonnette R. Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. *N Engl J Med.* 2021 Dec 9;385(24):2219-2229. doi: 10.1056/NEJMoa2103629. PMID: 34879448
- 2021 Foley P, Reich K, Blauvelt A, Bagel J, Langley RG, Miller M, Ramachandran P, Yang YW, Shen YK, You Y, Lebwohl M, Griffiths CEM. Serious Gastrointestinal-Related Adverse Events Among Psoriasis Patients Treated With Guselkumab in VOYAGE 1 and VOYAGE 2. *J Drugs Dermatol.* 2021 Aug 1;20(8):855-860. doi: 10.36849/JDD.6216. PMID: 34397205
- 2021 Blauvelt A, Armstrong AW, Langley RG, Gebauer K, Thaçi D, Bagel J, Guenther LC, Paul C, Randazzo B, Flavin S, Hsu MC, You Y, Reich K. Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. *J Dermatolog Treat.* 2021 Aug 4:1-8. doi: 10.1080/09546634.2021.1959504. Online ahead of print. PMID: 34348574
- 2021 Bagel J. Treatment strategies, management of comorbidities, and the role of IL-23 inhibitors in moderate to severe psoriasis. *Am J Manag Care.* 2021 Jun;27(10 Suppl):S203-S208. doi: 10.37765/ajmc.2021.88675. PMID: 34110117
- 2021 Bagel J, Glick B, Wu JJ, Chopra I, Song X, Brouillette M, Mendelsohn A, Rozzo S, Han G. Dose escalation and associated costs in biologic treatment of psoriasis based on real-world data. *J Med Econ.* 2021 Jan-Dec;24(1):782-791. doi: 10.1080/13696998.2021.1937187. PMID: 34107834.3
- 2021 Blauvelt A, Gordon KB, Lee P, Bagel J, Sofen H, Lockshin B, Soliman AM, Geng Z, Zhan T, Alperovich G, Stein Gold L. Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation

- administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis. *J Dermatolog Treat.* 2021 May 5:1-9. doi: 10.1080/09546634.2021.1914812. Online ahead of print. PMID: 33947295
- 2021 Warren RB, Blauvelt A, Bagel J, Papp KA, Yamauchi P, Armstrong A, Langley RG, Vanvoorden V, De Cuyper D, Cioffi C, Peterson L, Cross N, Reich K. Bimekizumab versus Adalimumab in Plaque Psoriasis. *N Engl J Med.* 2021 Jul 8;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23. PMID: 33891379
- 2021 Bagel J, Butler B, Nelson E, Hetzel A. A Retrospective Review of Patients' Response to Biologic Therapy for Psoriasis. *J Drugs Dermatol.* 2021 Apr 1;20(4):442-449. doi: 10.36849/JDD.2021.5823. PMID: 33852233
- 2021 Merola JF, Bagel J, Almgren P, Røpke MA, Lophaven KW, Vest NS, Grewal P. Tralokinumab does not impact vaccine-induced immune responses: Results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. *J Am Acad Dermatol.* 2021 Jul;85(1):71-78. doi: 10.1016/j.jaad.2021.03.032. Epub 2021 Mar 17. PMID: 33744356.
- 2021 K. Reich, U. Mrowietz, A. Menter, C.E.M. Griffiths, J. Bagel, B. Strober, N. Nunez Gomez, R. Shi, B. Guerette, M. Leibold. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. *J Eur Acad Dermatol Venereol.* 2021 Dec;35(12):2409-2414. doi: 10.1111/jdv.17520. Epub 2021 Aug 23.
- 2021 Van Voorhees, A.S., et al. Efficacy and Safety of Apremilast in Patients with Moderate-to-Severe Plaque Psoriasis of the Scalp: Results up to 32 Weeks from a Randomized, Phase III Study." *British Journal of Dermatology*, vol. 185, no. 4, 2021, pp. 840–842. <https://doi.org/10.1111/bjd.20083>.
- 2021 Richard B. Warren, M.D., Ph.D., Andrew Blauvelt, M.D., Jerry Bagel, M.D., Kim A. Papp, M.D., Ph.D., Paul Yamauchi, M.D., Ph.D., April Armstrong, M.D., M.P.H., Richard G. Langley, M.D., Veerle Vanvoorden, M.Sc., Dirk De Cuyper, M.D., Christopher Cioffi, Ph.D., Luke Peterson, M.S., Nancy Cross, M.D., et al. Bimekizumab versus Adalimumab in Plaque Psoriasis. *N Engl J Med.* 2021 Apr 23. doi: 10.1056/NEJMoa2102388. Online ahead of print. PMID: 33891379
- 2021 Blauvelt A, Kempers S, Lain E, Schlesinger T, Tying S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR; Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. *N Engl J Med.* 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040.
- 2021 Merola JF, Bagel J, Almgren P, Røpke M, Lophaven KW, Vest NS, Grewal P. Tralokinumab Does Not Impact Vaccine-induced Immune

- Responses: Results From a 30-week, Randomized, Placebo-controlled Trial in Adults With Moderate-to-severe Atopic Dermatitis. *J Am Acad Dermatol*. 2021 Mar 17:S0190-9622(21)00577-6. doi: 10.1016/j.jaad.2021.03.032. Online ahead of print.
- 2020 Bagel J, Nelson E, Riley C, Hetzel A. Apremilast with Add-On Calcipotriene/Betamethasone Dipropionate for Treating Moderate to Severe Plaque Psoriasis. *J Drugs Dermatol*. 2020 Dec 1;19(12):1149-1155. doi: 10.36849/JDD.2020.5435.
- 2020 Bagel J, Nelson E, Zapata J, Hetzel A. Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis. *Dermatol Ther (Heidelb)*. 2020 Dec;10(6):1383-1396. doi: 10.1007/s13555-020-00454-z. Epub 2020 Oct 13.
- 2020 Pariser DM, Bagel J, Lebwohl M, Yosipovitch G, Chien E, Spellman MC. Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial. *J Am Acad Dermatol*. 2020 Jun;82(6):1314-1320. doi: 10.1016/j.jaad.2020.01.056. Epub 2020 Jan 30. PMID: 32007513
- 2020 A S Paller, M M B Seyger, G Alejandro Magariños, J Bagel, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). *Br J Dermatol* 2020 Aug;183(2):231-241. doi: 10.1111/bjd.19147. Epub 2020 Jun 15.
- 2020 J. Bagel, A. Blauvelt J. Nia P. Hashim M. Patekar A. de Vera K. Ahmad B. Paguet S. Xia E. Muscianisi M. Lebwohl. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY). *J Eur Acad Dermatol Venereol*. 2021 Jan;35(1):135-142. doi: 10.1111/jdv.16558. Epub 2020 Jun 8.
- 2020 Bagel J, Stolshek BS, Yang Y, Kricorian G, Kircik LH. Evaluation of Patient-Reported Outcomes With Etanercept in Moderate to Severe Plaque Psoriasis Patients After Therapy With Apremilast. *J Drugs Dermatol*. 2020 Apr 1;19(4):378-383. doi: 10.36849/JDD.2020.4910.
- 2020 Stein Gold L, Bagel J, Allenby K, Sidgiddi S. Betamethasone dipropionate spray 0.05% alleviates troublesome symptoms of plaque psoriasis. *Cutis*. 2020 Feb;105(2):97-102;E1.
- 2020 Bagel J, Thibodeaux QG, Han G. Halobetasol propionate for the management of psoriasis. *Cutis*. 2020 Feb;105(2):92-96;E4.
- 2020 David M Pariser, Jerry Bagel, Mark Lebwohl, Gil Yosipovitch, Elaine Chien, Mary C Spellman. Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial. *J Am Acad*

- Dermatol. 2020 Jun;82(6):1314-1320. doi: 10.1016/j.jaad.2020.01.056. Epub 2020 Jan 30.
- 2020 Blauvelt A, Papp K, Gottlieb A, Jarell A, Reich K, Maari C, Gordon KB, Ferris LK, Langley RG, Tada Y, Lima RG, Elmaraghy H, Gallo G, Renda L, Park SY, Burge R, Bagel J; IXORA-R Study Group. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. *Br J Dermatol.* 2020 Jun;182(6):1348-1358. doi: 10.1111/bjd.18851. Epub 2020 Jan 15.
- 2020 Natsis NE, Merola JF, Weinberg JM, Wu JJ, Orbai AM, Bagel J, Gottlieb AB. Treatment of Medicare Patients with Moderate-to-Severe Psoriasis who Cannot Afford Biologics or Apremilast. *Am J Clin Dermatol.* 2020 Feb;21(1):109-117. doi: 10.1007/s40257-019-00468-0.
- 2020 Bagel J, Lebwohl M, Israel RJ, Jacobson A. Immunogenicity and skin clearance recapture in clinical studies of brodalumab. *J Am Acad Dermatol.* 2020 Feb;82(2):344-351. doi: 10.1016/j.jaad.2019.05.094. Epub 2019 Jun 5.
- 2019 Ritchlin CT, Stahle M, Poulin Y, Bagel J, Chakravarty SD, Kafka S, Srivastava B, Langholff W, Gottlieb AB. Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. *BMC Rheumatol.* 2019 Nov 28;3:52. doi: 10.1186/s41927-019-0094-3. eCollection 2019.
- 2019 Bagel J, Kimmel G, Chima M, Kim HJ, Bares J, Yao CJ, Singer G, Kim SJ, Lebwohl M. Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed. *J Am Acad Dermatol.* 2019 Sep;81(3):857-859. doi: 10.1016/j.jaad.2019.05.007. Epub 2019 May 10.
- 2019 Bagel, J, M.D., *Biologic in Psoriasis: The Next Generation. Practical Dermatology*, 2019 Feb, Vol. 16, No. 2, pp 72-73.
- 2018 Jerry Bagel, Ahmed S Samad, Bradley S Stolshek, Girish A Aras, James B Chung, Gregory Kricorian, Leon H Kircik. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who have Failed Therapy With Apremilast, *Journal of Drugs in Dermatology* 2018 Oct. Vol. 17, Issue 10 pp. 1078-1082.
- 2018 Green LJ, Kerdel FA, Cook-Bolden FE, Bagel J, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials, *Journal of Drugs in Dermatology* 2018 Oct. Vol. 17 Issue 10 pp. 1062-1069.

- 2018 Stein Gold L, Bagel J, Lebwohl M, Lin T, Martin G, Pillai R. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis. *J Drugs Dermatol*. 2018 Dec 1;17(12):1290-1296.
- 2018 Bagel J, Samad AS, Stolshek BS, Aras GA, Chung JB, Kricorian G, Kircik LH. Open-Label Study to Evaluate the Efficacy of Etanercept Treatment in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed Therapy With Apremilast. *J Drugs Dermatol*. 2018 Oct 1;17(10):1078-1082.
- 2018 Green LJ, Kerdel FA, Cook-Bolden FE, Bagel J, Lin T, Martin G, Pillai R, Israel R, Ramakrishna T. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials. *J Drugs Dermatol*. 2018 Oct 1;17(10):1062-1069.
- 2018 Bagel J. Treat to Target in Psoriasis: A Real-World Experience With Biologics and Adjunctive Topical Therapy. *J Drugs Dermatol*. 2018 Aug 1;17(8):918.
- 2018 Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, Sheng K, Xia S, Gilloteau I, Muscianisi E, Blauvelt A, Lebwohl M. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate-to-Severe Plaque Psoriasis (16-Week Clairty Results), *Dermatology and Therapy (Heidelb)*, 2018 Oct., Vol 10, pp. 1007.
- 2018 Bagel J, Tyring S, Rice KC, Collier DH, Kricorian G, Chung J, Iles J, Stolshek BS, Kaliyaperumal A, Papp KA. Open-Label Study of Etanercept Treatment in Patients With Moderate-to-Severe Plaque Psoriasis Who Lost A Satisfactory Response to Adalimumab. *Br J Dermatol*. 2018, 177 pp. 411-418.
- 2018 Sugarman JL, Weiss J, Tanghetti EA, Bagel J, Yamauchi PS, Stein Gold L, Lin T, Martin G, Pillai R, Israel R. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies. *J Drugs Dermatol*. 2018 Aug 1;17(8):855-861.
- 2018 Bagel J, Zapata J, Nelson E. A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy. *J Drugs Dermatol*. 2018 Aug 1;17(8):845-850.
- 2018 Bagel J, Schwartzman S. Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists. *Am J Clin Dermatol*. 2018 Dec;19(6):839-852. doi: 10.1007/s40257-018-0377-2.
- 2018 Ford AR, Siegel M, Bagel J, Cordero KM, Garg A, Gottlieb A, Green LJ, Gudjonsson JE, Koo J, Lebwohl M, Liao W, Mandelin AM 2nd,

- Markenson JA, Mehta N, Merola JF, Prussick R, Ryan C, Schwartzman S, Siegel EL, Van Voorhees AS, Wu JJ, Armstrong AW. Dietary Recommendations for Adults With Psoriasis or Psoriatic Arthritis From the Medical Board of the National Psoriasis Foundation: A Systematic Review. *JAMA Dermatol.* 2018 Aug 1;154(8):934-950. doi: 10.1001/jamadermatol.2018.1412.
- 2018 Bagel, J, M.D., Treat to Target in Psoriasis; A Real-World Experience With Biologics and Adjunctive Topical Therapy. *Journal of Drugs in Dermatology* 2018 Aug. 2018 Vol. 17, Issue 8 pp. 918
- 2018 Bagel J, Nia J, Hashim PW, Patekar M, de Vera A, Hugot S, Sheng K, Xia S, Gilloteau I, Muscianisi E, Blauvelt A, Lebwohl M. Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results). *Dermatol Ther (Heidelb).* 2018 Dec;8(4):571-579. doi: 10.1007/s13555-018-0265-y. Epub 2018 Oct 17.
- 2018 Feldman SR, Bagel J, Namak S. Biosimilars for Immune-Mediated Chronic Diseases in Primary Care: What a Practicing Physician Needs to Know. *Am J Med Sci.* 2018 May;355(5):411-417. doi: 10.1016/j.amjms.2017.12.014. Epub 2017 Dec 29.
- 2018 Bagel, J. M.D., M.S., Nelson, Elise, LPN, CCRC & Keegan, B. M.D. PhD. Open-Label, Observational Pilot Study Evaluating Desoximetasone Topical Spray 0.25% Twice Daily in Patients With Psoriasis Being Treated With Biologic Agents, *Journal of Psoriasis and Psoriatic Arthritis* 2018, Vol. 3. pp. 10-14.
- 2018 Bagel J, Nelson E. An Open-label, Observational Study Evaluating Desoximetasone Topical Spray 0.25% in Patients with Scalp Psoriasis. *J Clin Aesthet Dermatol.* 2018 May;11(5):27-29. Epub 2018 May 1.
- 2018 Stein Gold L, Bagel J, Lebwohl M, Jackson JM, Chen R, Goncalves J, Levi E, Duffin KC. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naive Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL. *J Drugs Dermatol.* 2018 Feb 1;17(2):221-228.
- 2018 Bagel, J., M.D. & Stein Gold, L. et al. Efficacy and Safety of Apremilast in Systemic- and Biologic-Naïve Patients With Moderate Plaque Psoriasis: 52-Week Results of UNVEIL, *JDD* 2018 Feb. Vol. 17, Issue 2 pp. 221-228.
- 2018 Bagel, J., M.D., Transitioning Biologic and Systemic Therapies in Psoriatic Patients, Ch. 24 pp 241-245, Yamauchi, Paul S., Editor, *Biologic and Systemic Agents in Dermatology*; 24 pp 241-245.
- 2017 Bagel J, Gold LS. Combining Topical Psoriasis Treatment to Enhance Systemic and Phototherapy: A Review of the Literature. *J Drugs Dermatol.* 2017 Dec 1;16(12):1209-1222.

- 2017 Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. *J Am Acad Dermatol*. 2017 Oct;77(4):667-674. doi: 10.1016/j.jaad.2017.05.033. Epub 2017 Aug 2.
- 2017 Bagel J, Nelson E, Keegan BR. Apremilast and Narrowband Ultraviolet-B Combination Therapy for Treating Moderate-to-Severe Plaque Psoriasis. *J Drugs Dermatol*. 2017 Oct 1;16(10):957-962.
- 2017 Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, Goncalves J, Levi E, Callis Duffin K. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. *J Drugs Dermatol*. 2017 Aug 1;16(8):801-808.
- 2017 Bagel J, Duffin KC, Moore A, Ferris LK, Siu K, Steadman J, Kianifard F, Nyirady J, Lebwohl M. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study. *J Am Acad Dermatol*. 2017 Oct;77(4):667-674. doi: 10.1016/j.jaad.2017.05.033. Epub 2017 Aug 2.
- 2017 Duffin KC, Papp KA, Bagel J, Levi E, Chen R, Gottlieb AB. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2. *J Drugs Dermatol*. 2017 Feb 1;16(2):147-153.
- 2017 Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah KN, Weinberg JM, Williams MO, Wu JJ, Yamauchi PS, Van Voorhees AS. From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. *J Am Acad Dermatol*. 2017 Feb;76(2):290-298. doi: 10.1016/j.jaad.2016.10.017. Epub 2016 Nov 28.
- 2017 Callis Duffin K, Bagel J, Bukhalo M, Mercado Clement IJ, Choi SL, Zhao F, Gill A, Pangallo B, Shuler C, Mallbris L, Jackson K. Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A). *J Eur Acad Dermatol Venereol*. 2017 Jan;31(1):107-113. doi: 10.1111/jdv.13768. Epub 2016 Aug 8.

- 2016 Simpson EL, Bieber T, Guttman-Yassky E, Beck LA, Blauvelt A, Cork MJ, Silverberg JI, Deleuran M, Kataoka Y, Lacour JP, Kingo K, Worm M, Poulin Y, Wollenberg A, Soo Y, Graham NM, Pirozzi G, Akinlade B, Staudinger H, Mastey V, Eckert L, Gadkari A, Stahl N, Yancopoulos GD, Ardeleanu M; SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N Engl J Med*. 2016 Dec 15;375(24):2335-2348. doi: 10.1056/NEJMoa1610020. Epub 2016 Sep 30.
- 2016 Koo J, Tyring S, Werschler WP, Bruce S, Olesen M, Villumsen J, Bagel J. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris--A randomized phase II study. *J Dermatolog Treat*. 2016;27(2):120-7. doi: 10.3109/09546634.2015.1083935. Epub 2015 Oct 7.
- 2016 Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Moller A, Osterdal ML, Stein Gold L. The Aerosol Foam Formulation of the Fixed Combination Calcipotriene Plus Betamethasone Dipropionate Improves the Health-Related Quality of Life in Patients With Psoriasis Vulgaris: Results from the Randomized PSO-FAST Study. *J Drugs Dermatol*. 2016 Aug 1;15(8):981-7.
- 2016 Callis Duffin K, Bukhalo M, Bobonich MA, Shrom D, Zhao F, Kershner JR, Gill A, Pangallo B, Shuler CL, Bagel J. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. *Med Devices (Auckl)*. 2016 Oct 12;9:361-369. doi: 10.2147/MDER.S113752. eCollection 2016.
- 2015 Leonardi C, Bagel J, Yamauchi P, Pariser D, Xu Z, Olesen M, Østerdal ML, Stein Gold L. Efficacy and Safety of Calcipotriene Plus Betamethasone Dipropionate Aerosol Foam in Patients With Psoriasis Vulgaris--a Randomized Phase III Study (PSO-FAST). *J Drugs Dermatol*. 2015 Dec;14(12):1468-77.
- 2015 Griffiths CE, Reich K, Lebwohl M, van de Kerkhof P, Paul C, Menter A, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. *Lancet*. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10.
- 2015 Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. *N Engl J Med*. 2015 Oct;373(14):1318-28. doi: 10.1056/NEJMoa1503824.
- 2015 Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the

- Medical Board of the National Psoriasis Foundation. *JAMA Dermatol.* 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.
- 2015 Yamauchi PS, Bagel J. Next-generation biologics in the management of plaque psoriasis: a literature review of IL-17 inhibition. *J Drugs Dermatol.* 2015 Mar;14(3):244-53.
- 2014 Stein Gold L, Kircik L, Fowler J, Jackson JM, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Sugarman J, Liu H, Jacovella J; Ivermectin Phase 3 Study Group. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. *J Drugs Dermatol.* 2014 Nov;13(11):1380-6.
- 2014 Bagel J, Levi E, Tyring S, Knuckles ML. Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris. *J Drugs Dermatol.* 2014 Nov;13(11):1374-9.
- 2014 Bagel, J. Biosimilars. *J Drugs Dermatol.* 2014 Jul;13(7):788-90.
- 2014 Hugh J, Van Voorhees AS, Nijhawan RI, Bagel J, Lebwohl M, Blauvelt A, Hsu S, Weinberg JM. From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. *J Am Acad Dermatol.* 2014 Jan;70(1):168-77.
- 2013 Kircik L, Lebwohl MG, Del Rosso JQ, Bagel J, Stein Gold L, Weiss JS. Clinical study results of desoximetasone spray, 0.25% in moderate to severe plaque psoriasis. *J Drugs Dermatol.* 2013 Dec;12(12):1404-10.
- 2013 Tyring S, Bagel J, Lynde C, Klekotka P, Thompson EH, Gandra SR, Shi Y, Kricorian G. Patient-reported outcomes in moderate-to-severe plaque psoriasis with scalp involvement: results from a randomized, double-blind, placebo-controlled study of etanercept. *J Eur Acad Dermatol Venereol.* 2013 Jan;27(1):125-8. doi: 10.1111/j.1468-3083.2011.04394.x. Epub 2011 Dec 21.
- 2012 Kimball AB, Alavian C, Alora-Palli M, Bagel J. Weight loss in obese patients with psoriasis can be successfully achieved during a course of phototherapy. *J Eur Acad Dermatol Venereol.* 2012 Dec;26(12):1582-4. doi: 10.1111/j.1468-3083.2011.04361.x. Epub 2011 Nov 30.
- 2012 Bagel J, Lynde C, Tyring S, Kricorian G, Shi Y, Klekotka P. Moderate to severe plaque psoriasis with scalp involvement: a randomized, double-blind, placebo-controlled study of etanercept. *J Am Acad Dermatol.* 2012 Jul;67(1):86-92.

- 2012 Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr. Consensus guidelines for the management of plaque psoriasis. *Arch Dermatol*. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410.
- 2011 Lapolla W, Yentzer BA, Bagel J, Halvorson CR, Feldman SR. A review of phototherapy protocols for psoriasis treatment. *J Am Acad Dermatol*. 2011 May;64(5):936-49. doi: 10.1016/j.jaad.2009.12.054. Epub 2011 Mar 22.
- 2011 Jerry Bagel, M.D. Adalimumab Plus Narrowband Ultraviolet B Light Phototherapy for the Treatment of Moderate to Severe Psoriasis, *Journal of Drugs in Dermatology*, April 2011.
- 2010 Zeichner JA, Lebwohl MG, Menter A, Bagel J, Del Rosso JQ, Elewski BE, Feldman SR, Kircik LH, Koo J, Gold LS, Tanghetti E; Psoriasis Process of Care Consensus Panel. Optimizing topical therapies for treating psoriasis: a consensus conference. *Cutis*. 2010 Sep;86(3 Suppl):5-31; quiz 32.
- 2010 Bagel, J. Treatment of Pediatric Psoriasis: *Practical Dermatology*, September 2010
- 2009 Bagel, J. Topical Therapies for the Treatment of Plaque Psoriasis: *Cutaneous Medicine for the Practitioner*, Vol. 84, No. 4S pgs. 3-13, October 2009
- 2009 Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, Van Voorhees AS; National Psoriasis Foundation. Treatment of intertriginous psoriasis: From the Medical Board of National Psoriasis Foundation: *J Am Acad Dermatology*, 2009 January; 60 (1): pgs. 120-124
- 2009 Bagel, J. Understanding PML and Risks Associated with Biologic Therapies: *Practical Dermatology*, Vol. 6, No. 5 pgs. 26-27, May 2009.
- 2009 Bagel, J. Treatment of Effective Therapy: Lead Psoriasis Patients Along the Path to Clearance, *Practical Dermatology*, Vol. 6, No. 2, pgs. 42-47, February 2009.
- 2009 Bagel, J. LCD Plus NB-UVB reduces Time to Improvement of Psoriasis vs. NB-UVB Alone, *Journal of Drugs in Dermatology*, Vol. 8 Issue 4 April 2009.
- 2009 Kalb RE, Bagel J, Korman NJ, Lebwohl MG, Young M, Horn EJ, Van Voorhees AS; Treatment of intertriginous psoriasis: From the Medical

Board of the National Psoriasis Foundation, *Journal of the American Academy of Dermatology*, Vol. 60, Issue 1, January, 2009.

- 2008 Bagel, J. Topical Psoriasis Therapy: Patients' Experiences, Physicians' Perceptions Don't Always Match, *Practical Dermatology*, Vol. 5, No. 2, pgs 58-61, February, 2008.
- 2008 Kircik LI, Bagel J, Korman N, Menter A, Elmets CA, Koo J, Yang YC, Chiou CF, Dann F, Stevens SR; Unite Study Group. Utilization of Narrow-Band Ultraviolet Light B Therapy and Etanercept for the Treatment of Psoriasis (UNITE): Efficacy, Safety, and Patient-Reported Outcomes, *Journal of Drugs in Dermatology*, January, 2008.
- 2008 Lebwohl MI, Bagel J, Gelfand JM, Gladman D, Gordon KB, Hsu S, Kalb RE, Kimball AB, Korman NJ, Krueger GG, Mease P, Morison WL, Paller A, Pariser DM, Ritchlin C, Strober B, Van Voorhees A, Weinstein GD, Young M, Horn L. From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis, *Journal of the American Academy of Dermatology*, Vol. 58, No. 1 pgs 94-105, January, 2008.
- 2007 Bagel, J. Be Prepared to Treat Pustular Psoriasis—An Uncommon Variant, *Practical Dermatology*, Vol. 4, No. 12, pg. 43, December, 2007.
- 2007 Bagel, J. Choosing the Safest Psoriasis Treatment for Women of Childbearing Potential, *Practical Dermatology*, Vol. 4, No. 11, pg. 50-51, November, 2007.
- 2007 Bagel, J. Effective Strategies To Treat Intertriginous Psoriasis, *Practical Dermatology*, Vol. 4, No. 10, pg. 54-58, October, 2007.
- 2007 Jerry Bagel, M.D., Responding to the Potential Effects of Obesity on Psoriasis, *Practical Dermatology*, Vol. 4, No. 9, pg. 46-47, September, 2007.
- 2007 Bagel, J. Building Long-Term Relationships as a Patient Caregiver, *Practical Dermatology*, Vol. 4, No. 8, pg. 53-54, August, 2007.
- 2007 Bagel, J. Get Familiar with the Biologics Safety Dance, *Practical Dermatology*, Vol. 4, No. 7, pg. 17-18, July, 2007.
- 2007 Bagel, J. Guidelines for Use of PUVA and Tips for Success, *Practical Dermatology*, Vol. 4, No. 6, pg. 56-57, June, 2007.
- 2007 Bagel, J. Psoriasis Research You and Your Patients Can Take to the Bank, *Practical Dermatology*, Vol. 4, No. 5, pg. 56-58, May, 2007.
- 2007 Bagel, J. Exploring Off-Label Use of Biologics for Dermatologic Indications, *Practical Dermatology*, Vol.4, No.5, pg.56-58. April, 2007.

- 2007 Bagel, J. et al., Assessment and tracking of long-term alefacept safety, *Journal of the American Academy of Dermatology*, Vol.56, Issue 2, Supplement2, February, 2007.
- 2007 Bagel, J. et al. National Psoriasis Foundation Clinical Consensus on Disease Severity, *Archives of Dermatology*, Vol. 143, February, 2007.
- 2007 Bagel, J. Evaluating the Risks and Benefits of Soriatane, *Practical Dermatology*, Vol. 4, No. 2, pg. 82-84, February, 2007.
- 2007 Bagel, J. New Perspectives on Methotrexate and Liver Biopsies, *Practical Dermatology*, Vol. 4, No. 1, pg. 74-75, January, 2007.
- 2006 Bagel, J. How and When to Use Cyclosporine in Psoriasis Care, *Practical Dermatology*, Vol..3, No. 12., pg. 58-61, December, 2006.
- 2006 Bagel, J. *Practical Dermatology*: In the Pipeline: Promising Early Data for a New Biologic. November, 2006: 3:11 pg. 25-26.
- 2006 Bagel, J. *Practical Dermatology*: Approaches to Difficult-to-Treat Psoriasis in Specialized Areas. October, 2006: 3:10 pg 48-50.
- 2006 Koo JY, Bagel J, Sweetser MT, Ticho BS. *Journal of Drugs in Dermatology*, Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study (the "Manuscript"). July/August, 2006
- 2006 Bagel, J. Unlock the Benefits of Phototherapy for Psoriasis: *Practical Dermatology*, April, 2006: pg. 41
- 2005 Bagel, J. Psoriasis Combination Therapy: Psoriasis Forum
- 2005 Bagel, J. Decision points for the initiation of systemic treatment for psoriasis: *Journal of the American Academy of Dermatology*, 53:101, 2005
- 2005 Bagel, J. Chordoma Cutis: *Journal of the American Academy of Dermatology*, 52:S105, 2005
- 2002 Lowe NJ, Gonzalez J., Bagel, J., et al. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. *Int J Dermatol* 2003;42:224-230.
- 2002 Bagel, J. A guide to Introducing Biologic Therapies for Psoriasis into Clinical Practice: Precept Medical Communications
- 2001 Ellis CN, Krueger GG; Alefacept Clinical Study Group.. Treatment of Chronic Plaque Psoriasis by Selective Targeting of Memory Effector T Lymphocytes: *New England Journal of Medicine*, 345:248, 2001

- 1999 Bagel, J. Establishing a Practical and Effective Psoriasis Treatment Center: *Dermatologic Clinics of North America*, April, 2000
- 1998 Bagel J, Garland WT, Breneman D, Holick M, Littlejohn TW, Crosby D, Faust H, Fivenson D, Nichols J. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: A double-blind, phase II multicenter trial; *Journal of American Academy of Dermatology*, 38:938, 1998
- 1985 Bagel, J. Subcutaneous Nodules in Pseudomas Septicemia; *American Journal of Medicine*, 80:528, 1986
- 1985 Bagel, J. Hemorrhagic Bullae Associated with Morganella Morganii Septicemia; *Journal of the American Academy of Dermatology*, 12:575, 1985
- 1985 Bagel, J. Wavelength Dependence for 4', 5' – Monoadduct Formulation in UVA Irradiated 8-Methoxypsoralen and Calf Thymus DNA; *Photochemistry and Photobiology*, 42:95, 1985
SPEAKING BUREAU
- Present Speaker Bureau: Eli-Lilly, Janssen, Abbvie, BMS, Incyte, Dermavant.
- 2003-Present International Speaker including: Canada, Venezuela, Colombia, Argentina, France, Austria, Italy, Greece, Israel, Egypt, Slovenia.

MEDICAL EDITOR

- 2006 Practical Dermatology
- 2010 Psoriasis Forum

HOSPITAL AFFILIATIONS

Penn Medicine Princeton Health at Princeton NJ – Senior Attending Physician

APPOINTMENTS

Clinical Professor of Dermatology at Icahn School of Medicine at Mt Sinai.

Clinical Associate Professor of Dermatology at University of Pisa

National Psoriasis Foundation Medical Advocacy Board

National Psoriasis Foundation Board of Directors

FOREIGN LANGUAGES SPOKEN

Italian, Yiddish, French

AWARDS

2018 National Psoriasis Foundation: Excellence in Leadership Award
2018 Inside Jersey: Top Doctor
2017 Inside Jersey: Top Doctor
2016 Mercer County Medical Society Award for Excellence in Research and Patient Advocacy
2016 National Psoriasis Foundation: Outstanding Physician Clinician Award
2016 American Academy of Dermatology: Presidential Citation
2016 Inside Jersey: Top Doctor
2015 Inside Jersey: Top Doctor
2014 Inside Jersey: Top Doctor
2013 Inside Jersey: Top Doctor
2012 Inside Jersey: Top Doctor
2011 Inside Jersey: Top Doctor
2010 Inside Jersey: Top Doctor
2009 Inside Jersey: Top Doctor
2008 Patients' Choice Award
2008 New York Metro Area: Top Doctor
2007 New York Metro Area: Top Doctor
2007 National Psoriasis Foundation Volunteer of the Year
2006 President's Council Leader: National Psoriasis Foundation
2006 New York Metro Area: Top Doctor
2005 New Jersey Life: Doctor of the Year
2005 New York Metro Area: Top Doctor
2004 New York Metro Area: Top Doctor
2003 New Jersey Magazine: Doctor of the Year
2002 Golden Triangle Award
2001 New Jersey Magazine: Doctor of the Year
1997 Robert Wood Johnson Distinguished Volunteer Faculty Award

INTERESTS

Italian
Physical Fitness
Baseball